however, its use in combination with other analgesics can offset these complications by reducing the dose of propofol 7 .
Dexmedetomidine, a selective α 2 -adrenoceptor agonist with sedative and analgesic effects, has been successfully used during colonoscopy 8 and ESD 9 .
Dexmedetomidine suppresses gastrointestinal motility and inhibits gastric emptying in healthy volunteers 10 whereas propofol does not 11 . Suppressing gastric motility may be crucial for successful ESD.
In this study, we compared the procedural efficacy and patient safety of the use of dexmedetomidine-remifentanil versus propofol-remifentanil during ESD.
II. MATERIALS AND METHODS Both the endoscopists and patients were blinded to the sedation protocol.
None of the patients were pre-medicated. Hartman's solution was administered at a rate of 3-5 mL/kg/h, and 2 L/min oxygen was given through a nasal cannula.
Oxygen saturation (SpO 2 ), systolic and diastolic blood pressure (SBP and DBP), electrocardiogram (ECG), and heart rate (HR) were monitored continuously and recorded at 5-min intervals.
The MOAA/S scale score was recorded as follows: just before the procedure (baseline, T0); 1 min after induction of sedation (1 min after a 5 min loading of dexmedetomidine in the DR group and 1 min after the propofol bolus injection in the PR group, T1); as the endoscope was passed into the esophagus (T2); as the tumor margin was marked by argon plasma coagulation (T3); 5 min after normal saline containing epinephrine (0.01 mg/mL) injection was given in the gastric submucosa (T4); at dissection of the gastric tumor region from the gastric submucosa (T5); once bleeding control was performed at the gastric bed after dissection (T6); and at the end of the procedure (T7).
Butylscopolamine (20 mg) was administered to suppress gastric motility during the procedure at the request of the endoscopist.
The discharge Aldrete score (Table 2 ) was recorded to document the patient's general status at the end of the procedure.
All patients were observed in the post-anesthetic care unit (PACU) until their discharge Aldrete score reached 10. 
가. Assessment of procedural performance
The ease of advancing the scope through the throat (four grades: very easy, easy, slight difficulty, and difficult), gastric motility 12 (no, mild, moderate, and vigorous) (Table 3) , and procedural satisfaction (very good, good, fair, and bad) were evaluated by the endoscopist. Patients were also asked about their satisfaction with the procedure (very good, good, bearable, and unbearable) before discharge from the PACU. The total amount of butylscopolamine used was recorded. Calculation of sample size was adopted by the previous study 13 which compared the efficacy and safety of dexmedetomidine with propofol TCI during endoscopic esophageal intervention. In which, 32 patients per group (α=0.05, 1-β=0.8 and 20% drop out) were calculated. Therefore, we intended to enroll 30 patients per group with a 10% of drop out rate.
III. RESULTS
No significant differences were observed in patient demographic data such as age, sex ratio, height, weight, snoring history, ASA classification, or sedation duration (Table 4) .
Tumor characteristics, including histology, macroscopic appearance, location and size measured by the endoscopist were similar between the groups (Table 5) . the DR group and propofol in the PR group were infused at rates of 0.47 ± 0.3 μg/h/kg and 23.8 ± 16.5 μg/min/kg, respectively. The infusion rates of remifentanil were 5.74 ± 1.44 μg/h/kg and 6.34 ± 4.02 μg/h/kg in the DR and PR groups, respectively (P = 0.451). Additional propofol requirements were 16.9 ± 10.3 mg in 8 patients of DR group and 13.3 ± 5.8 mg in 3 patients of PR group (P = 0.081) ( Table 6 ). Although the endoscope was more easily advanced through the throat in the PR group than in the DR group (P = 0.01), low-grade gastric motility (no or mild) was more frequent in the DR group (96.6% vs. 73.3%, P = 0.013). The butylscopolamine was administered in 10 patients of PR group compared with 4 patients of DR group (P = 0.078).
While the endoscopists were satisfied with the procedural performance and judged the procedures as favorable (P = 0.042) in all patients in the DR group and in 86.7% of patients in the PR group, patient satisfaction was comparable between the two groups ( Table 7 ).
The Aldrete score at the end of the procedure was not different between the groups (9.5 ± 0.6 in the DR group and 9.4 ± 0. 
IV. DISCUSSION
We found that minimal sedation using dexmedetomidine-remifentanil was safe for patients, and that endoscopists were satisfied with the procedural efficacy perhaps due to lower gastric motility.
This study has some clinical implications regarding the sedating protocol for ESD. First, our results suggest the importance of analgesics and optimal sedation level to avoid patient anxiety. ESD was safely performed under MOAA/S sedation levels of 4-5 if adequate analgesic was provided. As shown in Figure 1 , no patient needed management due to hemodynamic instability or adverse respiratory events despite the decreased HR in the DR group. We believe that continuous infusion of remifentanil enabled patients to tolerate this procedure well in an orientated and anxiety-free state. The analgesic requirement for a painful procedure was evident in a previous colonoscopy trial, which was terminated early before enrolling the planned number of patients because of the higher rate of supplemental fentanyl required and adverse hemodynamic events in the group of patients administered dexmedetomidine alone 14 . In fact, the sedation level for endoscopic procedures is controversial.
International sedation guidelines for gastrointestinal endoscopic procedures 15, 16 recommend sedating patients to improve procedural performance. However, Kiriyama et al. 17 assessed the effects of a bolus of 0.5 mg/kg propofol injected before ESD compared to no bolus of propofol, found that the propofol bolus decreased pharyngeal muscle tone and obtunded the scope-stimulated pharyngeal reflex in 77% of patients compared to 21% of patients with no bolus. Therefore, in the present study, the intact pharyngeal function in the DR group may have made it more difficult for the endoscopists to advance the scope into the throat, because our sedation protocols included a bolus 0.5 mg/kg propofol or dexmedetomidine known to preserve the pharyngeal tone.
Inhibiting gastric motility is crucial to successfully perform ESD, and this is the first report of endoscopist-evaluated gastric motility during ESD, in relation to two different sedation protocols (Table 6 ). The endoscopists graded gastric motility as low (no and mild among four grades) in 96.6% of the DR group and in 73.3% of the PR group (P = 0.013). This result was also noted as less of a requirement for butylscopolamine to suppress gastric motility. The effects of dexmedetomidine on gastric motility seemed to differ according to subject and dosage. In a previous study, infusion with a 1.0 µg/kg loading dose for 20 min followed by infusion of 0.7 µg/h/kg inhibited gastric emptying in healthy Dexmedetomidine itself does not alter gastric motility in rats but markedly enhances the inhibitory effect of morphine on gastric motility 19 . We are uncertain of the interactive effect of dexmedetomidine and remifentanil on gastric motility. As another evaluation of performance efficacy, the endoscopists were able to perform 94.4% of the complete resections of 36 en bloc resections (DR group) and 100% of the complete resections of 32 en bloc resections (PR group), suggesting that both sedation protocols were effective and safe for ESD.
Our study had some limitations. We analyzed a small number of patients, which limited the statistical power of our results. Gastric motility did not differ between the two groups (P = 0.101) when measured using the four grades (no, mild, moderate, and vigorous); however, there was a significant difference when just two grades of low (no/mild) and high (moderate/vigorous) were applied (P = 0.013). This same issue was also observed with the statistical analysis of endoscopist satisfaction. We did not find any statistical difference when the ratings were based on four grades (very good, good, fair, and bad).
However, when satisfaction was divided into favorable (very good/good) and unfavorable (fair/bad), endoscopists were in favor of the DR group treatment (favorable, 100% in DR group vs. 86.7% in PR group, P = 0.042). Although we intended this to be a prospective endoscopist-blinded study, we are unsure whether each endoscopist was aware of the type of sedative drugs because of the difference in the pharmacologic properties between dexmedetomidine and propofol even though we covered the patient's venous access site with a drape.
Therefore, we could not conclusively eliminate any bias of personal preference when they answered the questionnaires. Finally, our study design did not include a psychometric test for patients or comprehensive questionnaires to assess patient and endoscopist satisfaction as suggested by Vargo 20 .
In conclusion, use of dexmedetomidine and remifentanil targeting minimal sedation resulted in safe and effective ESD procedures, perhaps by suppressing gastric motility. However, further studies with a greater number of subjects may be required.
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